Nephrology

In a late-breaking abstract, investigators assess how discontinuation of ACEi or ARBs impact disease progression for advanced CKD.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

Approximately 1 out of every 6 patients with COVID-19 had a reduced eGFR.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

The common inherited condition autosomal dominant polycystic kidney disease (ADPKD) remains elusive when presented in primary care due to its nonspecific symptoms.

It is the first FDA-approved product indicated to improve kidney function in adults with HRS.

In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

The investigational therapy is being evaluated in a phase 2 study for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD on hemodialysis.

Investigators identified a correlation between severity of kidney-urinary tract complications and the affected protein involved with intermediate junctional epidermolysis bullosa (JEB).

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

Event rates were inversely proportional to kidney function in patients with chronic coronary disease.

According to the results, individuals with SCT who previously had COVID-19 also had various preexisting kidney conditions that were associated with poor outcomes.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Dr. Miriam Vos details the TARGET-NASH study, which indicated a higher prevalence of NAFLD in pediatric patients than previously thought.

The VersiPD Cycler System is expected to be available in the US in 2022.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.